ArticleNature reviews. Neuroscience2013
Effects of Schedule I drug laws on neuroscience research and treatment innovation.
Article in Nature reviews. Neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 5 syntheses or guidelines pooled it, 336 citations in OpenAlex.
- The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing.Frontiers in psychiatry · 2026Pooled it
- A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019.Medical cannabis and cannabinoids · 2021Pooled it
- Dose-response relationships of psilocybin-induced subjective experiences in humans.Journal of psychopharmacology (Oxford, England) · 2021Pooled it
- Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.Psychological medicine · 2020Pooled it
- Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials.Frontiers in psychiatry · 2019Pooled it
- Evaluating the attitudes of mental health professionals towards trials of MDMA: a randomised vignette trial.BMJ open · 2022Trial
- The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity.Biological psychiatry · 2015Trial
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.Journal of psychopharmacology (Oxford, England) · 2014Trial
- Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.Current drug abuse reviews · 2014Trial
- Article
- Psychedelics and neurostimulation for treatment resistant psychiatric disorders.Discover mental health · 2026Review
- Psycholytic Therapy Using LSD: a Realist Review.Brain and behavior · 2026Review
- India's Unique Legal Framework for Psilocybin Mushroom Research: An Unprecedented Opportunity in Psychiatric Therapeutics.Indian journal of psychological medicine · 2026Article
- Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Psilocybin: clinical potential, mechanistic insights, and biotechnological advances for scalable production.World journal of microbiology & biotechnology · 2025Review
- Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights.ACS chemical neuroscience · 2025Article
- A Tragedy of Errors: The State of Psychedelic Research in the Treatment of Alcohol Use Disorder.Brain sciences · 2025Review
- The Role of Psychedelics in Contemporary Psychological and Interdisciplinary Inquiry.Journal of personalized medicine · 2025Review
- Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.Psychopharmacology · 2025Review
- Integrating Systems Thinking and Behavioural Science.Behavioral sciences (Basel, Switzerland) · 2025Review
38 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Many psychoactive drugs are used recreationally, particularly by young people. This use and its perceived dangers have led to many different classes of drugs being banned under national laws and international conventions. Indeed, the possession of cannabis, 3,4-methylenedioxy-N-methylamphetamine (MDMA; also known as ecstasy) and psychedelics is stringently regulated. An important and unfortunate outcome of the controls placed on these and other psychoactive drugs is that they make research into their mechanisms of action and potential therapeutic uses - for example, in depression and post-traumatic stress disorder - difficult and in many cases almost impossible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.